Trials / Completed
CompletedNCT03176771
Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia
A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Fixed-Dose Study to Evaluate the Efficacy and Safety of MT-5199 for the Treatment in Patients With Tardive Dyskinesia (J-KINECT)
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 256 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of MT-5199 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-5199 | MT-5199 40 mg capsules |
| DRUG | Placebo | MT-5199 placebo capsules |
Timeline
- Start date
- 2017-06-21
- Primary completion
- 2020-09-29
- Completion
- 2020-09-29
- First posted
- 2017-06-05
- Last updated
- 2026-01-07
- Results posted
- 2023-08-14
Locations
82 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03176771. Inclusion in this directory is not an endorsement.